Generics Bulletin
>>Products
>>Biosimilars

Lupin Gives Direction On Pegfilgrastim And Ranibizumab

Neulasta Biosimilar Previously Slated For FY2021

13 Jan 2021

Indian major Lupin is continuing to further efforts on its three main growth drivers: biosimilars, inhalation products and long-acting injectables, management told the virtual J.P. Morgan Healthcare Conference in San Francisco.

Bulb — Lupin has ambitions to grow its biosimilars portfolio in the next two years • Source: Shutterstock

Lupin now intends to file its biosimilar Neulasta (pegfilgrastim) product in the US by the end of this calendar year, representing a delay from the 31 March 2021 financial year end for which it had previously planned.

Meanwhile, the Indian firm has kicked off a Phase III clinical comparison study for its biosimilar Lucentis (ranibizumab) candidate, LUBT010,...